Key result
Nebivolol at a dose of 1 mg/kg daily significantly improved survival in cardiomyopathic hamsters with congestive heart failure compared to control (p=0.042).
RCT (n=43)
randomly assigned
p-value: p=0.042
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for nebivolol in heart failure; prospective human trials needed before clinical adoption.
Donck et al. (1991) conducted an RCT in Congestive heart failure in cardiomyopathic hamsters (n=43). Nebivolol vs. Control food was evaluated on Survival (p=0.042). Nebivolol at a dose of 1 mg/kg daily significantly improved survival in cardiomyopathic hamsters with congestive heart failure compared to control (p=0.042).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: